NewLink Genetics Corp., an Ames-based biopharmaceutical company, announced today that it has received approval from an independent data safety monitoring committee that will enable it to continue with a key clinical study on a new treatment for pancreatic cancer patients. Following its review, the committee recommended that its "IMPRESS Phase 3 Pancreatic Cancer Trial With Algenpantucel-L" study should continue as planned, without modification. The review was conducted after 222 patient trials. NewLink's HyperAcute immunotherapy platform creates novel biologic products that are designed to stimulate the human immune system to recognize and attack cancer cells. "Now, with the first interim analysis behind us, we look forward to continuing the study and to gathering additional, more mature data in support of our mission to provide improved treatment options for patients with pancreatic cancer," said Dr. Nicholas. Vahanian, the company's president and chief medical officer.